GW Pharmaceuticals (PK) Stock Price

-0.485 (-6.06%)
Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
GW Pharmaceuticals Plc (PK) GWPRF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.485 -6.06% 7.515 16:08:06
Close Price Low Price High Price Open Price Previous Close
7.515 7.515 8.25 8.25 8.00
Bid Price Ask Price Spread News
7.24 8.75 1.51 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
15 400 $ 7.9741 $ 3,190 1,791 4.48 - 12.00
Last Trade Time Type Quantity Stock Price Currency
15:21:25 125 $ 7.515 USD

GW Pharmaceuticals (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 988.60M 131.55M - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
30.00 $ - 0.00% - -

more financials information »

GW Pharmaceuticals (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GWPRF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week7.808.257.258.071,558-0.285-3.65%
1 Month8.558.757.257.882,589-1.04-12.11%
3 Months10.6511.597.258.462,098-3.14-29.44%
6 Months9.5512.007.259.462,265-2.04-21.31%
1 Year9.9312.004.488.903,045-2.42-24.32%
3 Years8.4116.004.4811.384,565-0.895-10.64%
5 Years7.0816.003.009.944,8580.4356.14%

GW Pharmaceuticals (PK) Description

GW is a pharmaceutical group developing a portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic conditions. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines, including Sativex(R) Oromucosal Spray, to meet patient needs in a wide range of therapeutic indications. GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.